×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
ImmuPharma Major Shareholding Shift Noted - TipRanks.com
Tipranks
ImmuPharma plc (GB:IMM) has released an update. ImmuPharma plc has reported a change in major shareholdings, with Lanstead Capital Investors...
19 hours ago
ImmuPharma's Lupus therapy trial to commence in second half
Clinical Trials Arena
ImmuPharma has reported that its Phase II/III adaptive study of P140 (Lupuzor) is set to begin in the second half of this year.
10 months ago
ImmuPharma says phase III CRO has been chosen
Proactive Investors
Use of technology ... ImmuPharma PLC (AIM:IMM) said Simbec-Orion has been appointed as the contract research organisation (CRO) to carry out a...
4 months ago
ImmuPharma outlines new approach for lead asset aimed at significantly extending patent life
Proactive financial news
ImmuPharma PLC (AIM:IMM) has embarked on a new strategy to substantially boost the patent lifespan and market value of its P140 technology...
1 month ago
ImmuPharma Showcases Potential at BIO-Equity 2024 - TipRanks.com
Tipranks
ImmuPharma plc (GB:IMM) has released an update. ImmuPharma PLC, a biopharmaceutical company specializing in peptide-based therapeutics,...
1 week ago
AIM movers: Aquis-quoted Incanthera's revenue projections increases the value of Immupharma stake
UK Investor Magazine
Revenues could grow to £33m the following year. There is potential for licence deals in other countries. The Incanthera share price has jumped...
1 month ago
Proactive news headlines: Icanthera, Immupharma, i3, 88 Energy and more
Proactive financial news
Mining company Tungsten West PLC (AIM:TUN, OTC:TNGWF) has disclosed that the Environment Agency has commenced the six-week public...
1 month ago
ImmuPharma signs licence and development agreement with Avion
Pharmaceutical Technology
UK-based pharmaceutical company ImmuPharma has signed a licensing and development agreement with US-based Avion Pharmaceuticals for Lupuzor, a...
53 months ago
ImmuPharma positive about the 'short, medium and long-term', says CEO
Proactive Investors
Investors were told that it has funds to meet its immediate requirements, while the revenues for licensing deals for the non-US rights to P140,...
1 month ago